多西他赛作为一线用药治疗卵巢癌研究进展  

Advances of docetaxel as first line chemotherapy for epithelial ovarian cancer

作　　者：路虹[1] 王建东[1] 孔为民[1] 

机构地区：[1]首都医科大学附属北京妇产医院肿瘤科,北京100006

出　　处：《肿瘤防治杂志》2005年第15期1194-1196,共3页China Journal of Cancer Prevention and Treatment

摘　　要：多西他赛是半合成的紫杉类药物,临床药理学研究证实,多西他赛的抗瘤活性强于紫杉醇,并和紫杉醇没有交叉耐药。已有的研究表明,多西他赛治疗铂类耐药和对紫杉醇耐药的卵巢癌有较好的疗效。近几年,很多研究评价了多西他赛作为一线药物治疗卵巢上皮癌的价值。Ⅰ期和Ⅱ期的临床研究证实,多西他赛联合铂类药物作为一线药物治疗卵巢癌有较好的有效率为58%～89%,而多西他赛联合卡铂化疗的毒副反应比多西他赛联合顺铂少,特别是神经毒性。Ⅲ期临床研究比较了多西他赛联合卡铂方案和目前作为治疗卵巢上皮癌标准一线化疗方案的紫杉醇联合卡铂方案治疗卵巢上皮癌的差别,发现两个方案有相同的有效率,分别为58.7%和59.5%,但是多西他赛联合卡铂化疗的神经毒性更低,所以推荐多西他赛加卡铂联合化疗方案作为卵巢上皮癌的一线化疗方案。Docetaxel is obtained by semisynthesis from a noncytotoxic precursor, the needles of the European yew tree. There is evidence that docetaxel is active in platinum-resistant and paclitaxel-resistant ovarian cancers. Docetaxel currently is being evaluated as a component of first line combination chemotherapy for ovarian cancer. Phase Ⅰ-Ⅱ studise have shown that docetaxel-platinum doublets are highly effective in the treatment of ovarian cancer, with docetaxel-carboplatin providing a more favorable safety profile compared with docetaxel-cisplatin, particularly with respect to neurotoxicity. A phase III comparison of docetaxelcarboplatin versus paclitaxel-carboplatin supports the clinical use of docetaxel-carboplatin as first line chemotherapy for ovarian cancer, as it is shown to reduce the incidence of neurosensory toxicity compared with docetaxel-cisplatin.

关 键 词：卵巢肿瘤/药物疗法 紫杉酚/投药和剂量 综述文献 

分 类 号：R737.31[医药卫生—肿瘤]